| Not Yet Recruiting | MA-CRC-II-016 SHR-1811 NCT07355764 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects NCT07219940 | Shine-On Biomedical Co., Ltd. | Phase 1 |
| Recruiting | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing He NCT07436845 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Har NCT07032727 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC NCT07198165 | Ruijin Hospital | Phase 2 |
| Recruiting | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Al NCT07040956 | West China Hospital | Phase 2 |
| Recruiting | A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resect NCT07010120 | West China Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated NCT06971406 | Qiming Wang | Phase 2 |
| Recruiting | Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy NCT06764680 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted NCT06741982 | West China Hospital | Phase 1 |
| Not Yet Recruiting | Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC NCT06694129 | National Cancer Center, China | — |
| Active Not Recruiting | Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Can NCT07230080 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast C NCT06503380 | Fudan University | — |
| Recruiting | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver NCT06356584 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC NCT06142058 | Xueqin Yang | — |
| Recruiting | Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935 | Massachusetts General Hospital | N/A |
| Recruiting | Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer NCT05983107 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA NCT06307249 | Lebanese University | Phase 1 |
| Unknown | Donafenib for Recurrent Cervical Cancer NCT05310331 | Lei Li | Phase 2 |
| Unknown | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer NCT05311579 | Lei Li | Phase 2 |
| Completed | Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC NCT06818097 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Unknown | Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude NCT05063643 | Affiliated Hospital of Qinghai University | — |
| Completed | First-line Chemotherapy for Recurrent Cervical Cancer NCT04188847 | Lei Li | Phase 2 |
| Unknown | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal NCT05225844 | Harbin Medical University | Phase 2 |
| Recruiting | SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC NCT06889649 | Peking University First Hospital | Phase 2 |
| Completed | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer NCT04656249 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System NCT03185988 | Shen Lin | Phase 2 |
| Unknown | AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Tre NCT02504346 | Oslo University Hospital | Phase 2 |
| Recruiting | Neoadjuvant Treatment Modalities in Esophageal Cancer NCT04821843 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Recruiting | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer NCT04821778 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |